Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended
- Abstracts highlight pipeline programmes in precision oncology, including novel LSD1 inhibitor - Further detail on A2A programme, including novel biomarker for patient selection to be presented
Precision designed LSD1 and MALT1 inhibitors currently progressing through IND-enabling studies Both molecules demonstrate Exscientia's ability to overcome critical design challenges and identify